BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 1 clinical trial evaluating the pharmacokinetic and pharmacodynamic activity of ARRY-162, a novel small molecule MEK inhibitor, at the 2008 Annual European Congress of Rheumatology (EULAR) in Paris, France. This four-week, first-in-patient study of ARRY-162 was in patients with stable rheumatoid arthritis (RA) receiving continuing doses of methotrexate.
